<DOC>
	<DOCNO>NCT02550197</DOCNO>
	<brief_summary>The aim trial evaluate immunogenicity safety quadrivalent influenza vaccine ( QIV ) trivalent influenza vaccine ( TIV ) ( split-virion inactivate ) Northern Hemisphere ( NH ) 2015 2016 seasonal formulation , subject age 18 60 year Republic Korea registration QIV Ministry Food Drug Safety . Objectives : - To evaluate immunogenicity QIV TIV ( split-virion , inactivate ) NH 2015-2016 seasonal formulation . The compliance , term immunogenicity , QIV NH 2015-2016 formulation , requirement Committee Medicinal Products Human Use ( CHMP ) Note Guidance ( NfG ) CPMP/BWP/214/96 assess . - To evaluate safety profile QIV TIV ( split-virion , inactivate ) NH 2015-2016 seasonal formulation</brief_summary>
	<brief_title>Immunogenicity Safety Quadrivalent Influenza Vaccine Given Intramuscular Route Subjects Aged 18 60 Years</brief_title>
	<detailed_description>All subject receive one dose either QIV TIV Day 0 . They monitor safety immunogenicity Day 21 post-vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 18 60 year day inclusion Subjects age 18 year : Assent form sign date subject independent witness , informed consent form sign date least one parent another legally acceptable representative independent witness Subjects age 19 60 year : Informed consent form sign date subject independent witness Subject parent/legally acceptable representative ( applicable ) able attend schedule visit comply trial procedure Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior vaccination least 3 week vaccination ) Participation time study enrollment ( 4 week precede trial vaccination ) plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede trial vaccination plan receipt vaccine second visit , 3 week follow trial vaccination Vaccination influenza administer context clinical trial flu vaccination campaign selfreported history influenza infection ( influenzalike illness ) previous 6 month Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Known history seropositivity Human Immunodeficiency Virus ( HIV ) Hepatitis C Known systemic hypersensitivity egg , chicken protein , neomycin , formaldehyde octoxynol9 , vaccine component , history lifethreatening reaction vaccine use study vaccine contain substance Known suspect thrombocytopenia , contraindicate intramuscular vaccination , base Investigator 's judgment Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination , base Investigator 's judgment Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 38.0°C ) . A prospective subject include study condition resolve febrile event subside Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Quadrivalent influenza vaccine</keyword>
	<keyword>Trivalent influenza vaccine</keyword>
</DOC>